Tag: PCSK9 inhibitor
The European Commission authorise use of evolocumab to reduce risk of myocardial infarction in patients with established cardiovascular disease
The European Commission (EC) has authorised a new indication in the evolocumab (Repatha, Amgen) ...
ADVERTORIAL: Taking control of LDL-C when statin therapy is not enough
This content is for distribution within the UK only.
This content is for distribution wit...
ACC 2017: PCSK9 inhibitor evolocumab significantly reduces the risk of cardiovascular events
Data for a new drug that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) show tha...
AHA 2016: The Medicines Company and Alnylam Pharmaceuticals present positive results from ORION-1 phase 2 study of their PCSK9 inhibitor inclisiran
The Medicines Company and Alnylam Pharmaceuticals have announced positive results from the analysis ...
Pfizer discontinues the global development of its investigational PCSK9 inhibitor
Pfizer is to discontinue the global clinical development program for bococizumab—its investigational...
